Navigation Links
New Pixantrone Data Presented at Meetings at American Society of Hematology Conference
Date:12/6/2010

SEATTLE, Dec. 6, 2010 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. ("the Company") (Nasdaq and MTA: CTIC) today announced new pixantrone end of study ("EOS") follow up results from the Company's pivotal phase III PIX301 trial, which results form the basis for the Company's recent Marketing Authorization Application (the "MAA") currently under review by the European Medicines Agency ("EMA").

The end-of-study results showed continued improvement in the trial's primary and secondary endpoints with increased statistical confidence around the endpoint results. At EOS, CR/CRu (Complete Response ("CR")/Complete Response unconfirmed) rate increased to 24% in the pixantrone arm compared to 7% among comparator recipients (p=0.009) while ORR (Overall Response Rate) increased to 40% versus 14% for comparator recipients (p=0.001). The median duration of CR/CRu was 9.6 months for the pixantrone group compared to 4.0 months for the comparator group. Pixantrone patients experienced a 40% reduction in the risk of death or progression over the two year study observation and follow up period compared to standard chemotherapy (p=0.005, HR=0.60) and a 21% reduction in the overall risk for dying (p= 0.25, HR =0.79).  The most common grade 3, 4 adverse event observed on the pixantrone arm was neutropenia in 41.2% of patients versus 19.4% on the comparator arm. However, the incidence of serious infections was comparable between arms. Deaths due to an adverse event were identical between both arms; there were more LVEF reductions in pixantrone arm, however only two were grade 3 and all were asymptomatic. The results were presented by Principal Investigator, Ruth Pettengell, M.D. of St. George's Hospital, University of London, the lead investigator for the phase III PIX301 EXTEND trial. "The end of study results strengthen the confidence and stability across the primary and secondary measures of efficacy," noted Dr. Pettengell.  "The magnitude of complete and durable
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. EMEA Validates Cell Therapeutics, Inc.s (CTI) Expanded Pixantrone Pediatric Investigation Plan (PIP)
2. Cell Therapeutics, Inc. (CTI) Advances Pixantrone Filing Process in Europe; Submits Pediatric Investigation Plan (PIP)
3. Cell Therapeutics Second Quarter Net Loss Decreases 54%; Pixantrone NDA Submitted to the FDA for Approval
4. Pixantrone Significantly Increases Complete Remissions, Overall Response Rates, Frequency of Durable Remissions and Progression Free Survival in Patients with Relapsed and Refractory Aggressive Non-Hodgkins Lymphoma
5. Low Occurrence of Severe Cardiac Side Effects Despite Extensive Prior Doxorubicin Treatment Reported in Pixantrone Pivotal Trial
6. Cell Therapeutics Targeting Potential Zevalin Label Expansion, Pixantrone and OPAXIO Drug Approvals to Grow Commercial Operations and Revenues in 2009
7. Alder Biopharmaceuticals Announces That Data From Multiple Studies of ALD518 (BMS945429), an Investigational Antibody Therapeutic in Rheumatoid Arthritis Patients, to be Presented at Annual Meeting of the American College of Rheumatology
8. Week-24 Interim Results From Phase 2b PILLAR Study to be Presented as Late-Breaker at AASLD
9. Investigational Data Presented for INTUNIV™ (guanfacine) Extended-Release Tablets When Coadministered With Stimulants Showed ADHD Symptom Improvement in Overall, Morning and Evening Assessments
10. Amgen Highlights Data to Be Presented at American Society for Bone and Mineral Research (ASBMR) Meeting
11. Data on VIVUS QNEXA to be Presented in Six Posters at The Obesity Societys Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... 2014 OMICS Group’s 5th International conference ... August, 2014 at Double Tree by Hilton Beijing, China ... in Analytical & Bioanalytical research methods only to facilitate ... this occasion, Dr. Srinubabu Gedela, MD of OMICS Group ... a remarkable one in bringing a unique and international ...
(Date:7/10/2014)... ST. PETERSBURG, Russia , July 10, 2014 /PRNewswire/ ... the Russian Federation Dmitry Medvedev , presented ... a biopharmaceutical company BIOCAD . The Company is ... the scope of MabNext project BIOCAD develops a number ... of cancer and autoimmune diseases. The ceremony took place ...
(Date:7/10/2014)... Calif., July 10, 2014   Ceres, Inc . ... seed company, announced today financial results for the three ... on its business. Ceres reported that the ... product performance this growing season in Brazil, which concluded ... the company,s sorghum evaluation areas for part of the ...
(Date:7/10/2014)... today in the journal PNAS (Proceedings of the ... of day and sleep deprivation have a significant effect ... looking at the best time of day to test ... for administering medicines effectively. , Researchers from the University ... investigated the links between sleep deprivation, body clock disruption ...
Breaking Biology Technology:A Critical Review of Analytical Techniques for Improved Living Standards 2A Critical Review of Analytical Techniques for Improved Living Standards 3A Critical Review of Analytical Techniques for Improved Living Standards 4Dmitry Medvedev Presented BIOCAD the First National "Industry" Award 2Ceres Announces Fiscal Third Quarter 2014 Financial Results 2Ceres Announces Fiscal Third Quarter 2014 Financial Results 3Ceres Announces Fiscal Third Quarter 2014 Financial Results 4Ceres Announces Fiscal Third Quarter 2014 Financial Results 5Ceres Announces Fiscal Third Quarter 2014 Financial Results 6Ceres Announces Fiscal Third Quarter 2014 Financial Results 7Ceres Announces Fiscal Third Quarter 2014 Financial Results 8Ceres Announces Fiscal Third Quarter 2014 Financial Results 9Time of day crucial to accurately test for diseases, new research finds 2
... a simple and convenient technique that combines nanoscale ... elusive goal. With current analytical instruments, spatial resolution ... preparation too complex or sample size too large ... the University of Illinois have demonstrated a method ...
... LAKES, N.J., March 27 BD (Becton,Dickinson and ... medical technology,company, and Direct Relief International, a humanitarian ... volunteer,initiative to strengthen healthcare in Ghana. A team ... Ghana for three weeks and work side-by-side,with Direct ...
... (Nasdaq: GNTA ) announced that the NASDAQ ... an extension of,time to achieve full compliance with ... decision, the listing of the,Company,s common stock will ... NASDAQ Capital Market, effective with the open of ...
Cached Biology Technology:Femtogram-level chemical measurements now possible, U. of I. team reports 2BD and Direct Relief International Launch Second Volunteer Service Trip to Improve Healthcare in Ghana 2BD and Direct Relief International Launch Second Volunteer Service Trip to Improve Healthcare in Ghana 3Genta Granted Extension to Achieve Compliance with NASDAQ Listing Requirements 2Genta Granted Extension to Achieve Compliance with NASDAQ Listing Requirements 3
(Date:7/10/2014)... July 3, 2014 According to ... Type (Swipe And Area), Material (Optical Prism, Pizeoelectric, Capacitive, ... Security and Banking & Finance), and Geography - Global ... MarketsandMarkets, the global Fingerprint Sensors Market is projected to ... CAGR of 16.8% from 2014 to 2020. ...
(Date:7/10/2014)... Fingerprint Cards, (FPC,s) new mobile touch sensor FPC1021 ... Top 5 smartphone OEM has selected FPC1021 for a flagship ... 2014.   FPC is proud to announce this ... a planned date for the start of mass production in ... of 3 million units. The Chinese OEM wants to remain ...
(Date:7/10/2014)... 2014 Fingerprint Cards, (FPC,s) ... win (DW). An Asian OEM has selected FPC1021 for a ... in August 2014.   FPC is proud to ... a planned date for start of mass production in August ... SEK 5M, for delivery in the first half of July. ...
Breaking Biology News(10 mins):Fingerprint Sensors Market worth $14.35 Billion by 2020 2Fingerprint Sensors Market worth $14.35 Billion by 2020 3FPC Wins DW for 1021 Touch Sensor for Flagship Smartphone from Chinese Top 5 Smartphone OEM 2FPC Wins DW and Initial Ramp Order for FPC1021 Touch Sensor for Flagship Smartphone from Asian OEM 2
... School of Medicine has revealed key features in ... and other extreme environments. The researchers, funded by ... environment of Antarctica. They found subtle but significant ... and Haloarchaea, organisms that can tolerate severe conditions ...
... that pumpkins and cucumbers can be traced back to India. ... of Cucurbitaceae evolution and diversity, a new checklist of the ... that family. The study was published in the open access ... components of a healthy daily diet, not just in India ...
... of continuing evolution in the college textbook market, an ... leader (NYSE:JWa, JWb), and Rice University-based OpenStax College, a ... partnership calls for Wiley to deliver content from OpenStax ... online learning, practice and assessment resources that are ...
Cached Biology News:University of Maryland School of Medicine discovers adaptations to explain strategies for survival on Mars 2A new checklist confirms Indian origins of pumpkins and cucumbers 2Unlikely partners create innovative product for college biology 2
Recombinant Rhesus Macaque IFN-alpha...
... 500 g protein in 200 l SDS-PAGE ... cell lysate; Abelson transformed macrophage cells, ... positive control, should be stored ... be minimized, sample vial should ...
The epitope is specific for TASK and is not present in any other known proteins tested so far.,SPECIES REACTIVITIES: The epitope is also highly conserved between mouse and rat (17/18 residues iden...
Anti-Mouse MIP-1g, Biotin (Polyclonal) (rabbit IgG)...
Biology Products: